Antoney Ferrey is a Nephrology physician affiliated with University of California, Irvine. OpenAlex indexes 51 publications with 1,106 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 The City Dr S
Orange, CA 928683201
Telephone
714-880-7812Provider last certified this registry record 14 Nov 2022.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alnylam Pharmaceuticals Inc.Program year20251 payment
- Calliditas Therapeutics US Inc.Program year20251 payment
- SANOFI-AVENTIS U.S. LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
52.6%Calcium channel blocker11.4%Nifedipine Er72%Amlodipine Besylate28%Part D≥16 patientsBeta blocker11.2%Carvedilol83%Metoprolol Tartrate18%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
21.8%Corticosteroid11.9%Prednisone100%Part D≥17 patientsH2 blocker5.2%Famotidine100%Part D<11 patients+ 1 more class in this area
Genitourinary & hormones
7.1%alpha-Adrenergic Blocker7.1%Tamsulosin Hcl100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Hybrid Telemedicine and In‐Person Care for Kidney Transplant Follow‐Up: A Qualitative Study
Clinical Transplantation
2025 - Racial and Ethnic Disparities in Outcomes following Preemptive Kidney Transplant Waitlisting in the United States from 2009 to 2024
Journal of the American Society of Nephrology
2025 - Clinical Significance of Pre-Transplant Serum Albumin and Mortality in Pancreas Transplant Recipients
American Journal of Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Susan O’Brien, MD
University of California, Irvine
Steven Potkin, MD
University of California, Irvine
Stefan Ciurea, MD
University of California, Irvine
Farshid Dayyani, MD
University of California, Irvine
Andrew Levey, MD
Tufts Medical Center
Bertram Kasiske, MD
Hennepin Healthcare
Garabed Eknoyan, MD
Baylor College of Medicine
Lawrence Hunsicker, MD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”